Northland Securities Sticks to Their Hold Rating for Intrexon (XON)

By Carrie Williams

Northland Securities analyst Robert Breza maintained a Hold rating on Intrexon (XONResearch Report) today and set a price target of $7. The company’s shares closed yesterday at $4.34, close to its 52-week low of $3.95.

Breza observed:

“We believe the company will spin-off its healthcare assets as the company has undertaken a realignment to focus the company and reduce its cash burn.”

According to TipRanks.com, Breza is a 5-star analyst with an average return of 12.0% and a 59.2% success rate. Breza covers the Technology sector, focusing on stocks such as Coupa Software Inc, MobileIron, Inc., and Salesforce.com.

Intrexon has an analyst consensus of Moderate Buy, with a price target consensus of $25.

See today’s analyst top recommended stocks >>

Based on Intrexon’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $60.71 million. In comparison, last year the company had a GAAP net loss of $41.99 million.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is neutral on the stock. Most recently, in March 2019, Dean J. Mitchell, a Director at XON bought 8,906 shares for a total of $28,232.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intrexon Corp. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals.